tetano
Editor, Senior Moderator
CEN Case Rep
. 2023 May 27.
doi: 10.1007/s13730-023-00798-3. Online ahead of print. Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review
Mariko Teragaki[SUP] 1 [/SUP], Mari Tanaka[SUP] 2 [/SUP], Hiroko Yamamoto[SUP] 2 [/SUP], Tomoka Watanabe[SUP] 2 [/SUP], Jun Takeoka[SUP] 2 [/SUP], Awaisshafig Fukumi[SUP] 2 [/SUP], Kotaro Maeda[SUP] 2 [/SUP], Yohtaro Takami[SUP] 2 [/SUP], Hirona Saita[SUP] 2 [/SUP], Sachio Iwanari[SUP] 2 [/SUP], Masaki Ikeda[SUP] 2 [/SUP], Hiroya Takeoka[SUP] 2 [/SUP]
Affiliations
Mass vaccination is the most important strategy to terminate the coronavirus disease 2019 (COVID-19) pandemic. Reports suggest the potential risk of the development of new-onset or relapse of minimal change disease (MCD) following COVID-19 vaccination; however, details on vaccine-associated MCD remain unclear. A 43-year-old man with MCD, who had been in remission for 29 years, developed nephrotic syndrome 4 days after receiving the third dose of the Pfizer-BioNTech vaccine. His kidney biopsy revealed relapsing MCD. Intravenous methylprednisolone pulse therapy followed by oral prednisolone therapy was administered, and his proteinuria resolved within 3 weeks. This report highlights the importance of careful monitoring of proteinuria after COVID-19 vaccination in patients with MCD, even if the disease is stable and no adverse events occurred during previous vaccinations. Our case report and literature review of COVID-19 vaccine-associated MCD indicated that MCD relapse tends to occur later after vaccination and slightly more often following the second and subsequent vaccine doses than new-onset MCD.
Keywords: BNT162 vaccine; COVID-19 vaccine booster shot; Nephrotic syndrome; Recurrence; mRNA vaccines.
. 2023 May 27.
doi: 10.1007/s13730-023-00798-3. Online ahead of print. Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review
Mariko Teragaki[SUP] 1 [/SUP], Mari Tanaka[SUP] 2 [/SUP], Hiroko Yamamoto[SUP] 2 [/SUP], Tomoka Watanabe[SUP] 2 [/SUP], Jun Takeoka[SUP] 2 [/SUP], Awaisshafig Fukumi[SUP] 2 [/SUP], Kotaro Maeda[SUP] 2 [/SUP], Yohtaro Takami[SUP] 2 [/SUP], Hirona Saita[SUP] 2 [/SUP], Sachio Iwanari[SUP] 2 [/SUP], Masaki Ikeda[SUP] 2 [/SUP], Hiroya Takeoka[SUP] 2 [/SUP]
Affiliations
- PMID: 37244881
- DOI: 10.1007/s13730-023-00798-3
Mass vaccination is the most important strategy to terminate the coronavirus disease 2019 (COVID-19) pandemic. Reports suggest the potential risk of the development of new-onset or relapse of minimal change disease (MCD) following COVID-19 vaccination; however, details on vaccine-associated MCD remain unclear. A 43-year-old man with MCD, who had been in remission for 29 years, developed nephrotic syndrome 4 days after receiving the third dose of the Pfizer-BioNTech vaccine. His kidney biopsy revealed relapsing MCD. Intravenous methylprednisolone pulse therapy followed by oral prednisolone therapy was administered, and his proteinuria resolved within 3 weeks. This report highlights the importance of careful monitoring of proteinuria after COVID-19 vaccination in patients with MCD, even if the disease is stable and no adverse events occurred during previous vaccinations. Our case report and literature review of COVID-19 vaccine-associated MCD indicated that MCD relapse tends to occur later after vaccination and slightly more often following the second and subsequent vaccine doses than new-onset MCD.
Keywords: BNT162 vaccine; COVID-19 vaccine booster shot; Nephrotic syndrome; Recurrence; mRNA vaccines.